Is hyperlipazemia a poor prognostic factor in patients with COVID-19 ?

Year 2022, Volume: 5 Issue: 3, 720 - 725, 30.05.2022

Orhan Coşkun , Mustafa Çapraz , Mustafa Cihangiroğlu Ahmet Turan Kaya

https://doi.org/10.32322/jhsm.1057456

Abstract

Introduction: COVID-19 disease may pose a considerable health threat to healthy individuals and individuals with comorbidity. The SARS-CoV-2 virus affects the respiratory tract and may cause damage to the pancreas by binding to the ACE-2 receptor in the pancreas. In our study, we investigated the effects of hyperlipasemia on morbidity and mortality in patients diagnosed with COVID-19.
Material and Method: In this study, 2350 patients diagnosed with COVID-19 between November 2020 and December 2020 were retrospectively reviewed. Other possible causes of hyperlipasemia were excluded. Hyperlipasemia secondary to COVID-19 was detected in 338 patients. These patients were divided into two groups based on their lipase elevation rates.
Results: Hyperlipasemia was detected in 14.4% of the patients diagnosed with COVID-19, and severe hyperlipasemia (>3x) was detected in 2.3%. The mean age of the patients was 64±13.8 (18-92), of which 59.5% (201) were male. In our study, 24 patients (1%) were diagnosed with acute pancreatitis. When compared according to lipase level, a significant difference was found between the groups regarding the history of HT, CCI score, development of ARF at follow-up, development of ARDS, need for ICU hospitalization, need for intubation, length of stay in ICU, and death rates. A weak correlation was found in the correlation analysis between hyperlipasemia and ARDS development and mortality.
Conclusion: Elevated lipase levels were associated with poor prognosis and mortality in patients with COVID-19 infection.

Keywords

SARS-CoV-2, hyperlipasemia, COVID-19, pancreatitis, viral pancreatitis

Project Number

yok

References

• Akkus C, Yilmaz H, Mizrak S, Adibelli Z, Akdas O, Duran C. Development of pancreatic injuries in the course of COVID-19. Acta Gastroenterol Belg 2020; 83: 585-92.
• Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020; 92: 577-83.
• https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---24-august-2021.
• Sinonquel P, Aerts M, Badaoui A, et al. BSGIE survey on COVID-19 and gastrointestinal endoscopy in Belgium: results and recommendations. Acta Gastroenterol Belg 2020; 83: 344-54.
• Vege SS. Acute pancreatitis. Feldman M, Friedman LS, Brand LJ (editors). In: Sleisenger and Fordtran’s gastrointestinal and liver disease, Eleventh Edition, Chapter 58, p: 893-916.
• Mazrouei SSA, Saeed GA, Al Helali AA. COVID-19-associated acute pancreatitis: a rare cause of acute abdomen. Radiol Case Rep 2020; 15: 1601-3.
• Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 expression in pancreas may cause pancreatic damage after SARS-CoV-2 infection. Clin Gastroenterol Hepatol 2020; 18: 2128-30.e2.
• Banks PA, Bollen TL, Dervenis C, et al. Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-11.
• Wang F, Wang H, Fan J, Zhang Y, Wang H, Zhao Q. Pancreatic injury patterns in patients with COVID-19 pneumonia. Gastroenterology 2020; 159: 367e70
• Rasch S, Herner A, Schmid RM, Huber W, Lahmer T. High lipasemia is frequent in COVID-19 associated acute respiratory distress syndrome. Pancreatology 2021; 21: 306-11.
• McNabb-Baltar J, Jin DX, Grover AS, et al. Lipase Elevation in Patients with COVID-19. Am J Gastroenterol 2020; 115: 1286-8.
• Berk JE, Shimamura J, Fridhandler L. Amylase changes in disorders of the lung. Gastroenterology 1978; 74: 1313e7
• Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin N Am 1990; 19: 793e810.
• Hameed AM, Lam VW, Pleass HC. Significant elevations of serum lipase not caused by pancreatitis: a systematic review. HP 2015; 17: 99e112
• Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroentero 2014 20: 13879-92
• Rawla P, Bandaru SS, Vellipuram AR. Review of infectious etiology of acute pancreatitis. Gastroenterol Res 2017; 10: 153-8.
• de-Madaria E, Siau K, Cardenas-Jaen K. Increased amylase and lipase in patients with COVID-19 pneumonia: Don’t blame the pancreas just yet! Gastroenterology 2020. [Epub ahead of print April 21 2020.
• Thaweerat W. Current evidence on pancreatic involvement in SARSCoV- 2 infection. Pancreatology 2020; 20: 1013-4.
• Barlass U, Wiliams B, Dhana K, et al. Marked elevation of lipase in COVID-19 Disease: a cohort study. Clin Transl Gastroenterol 2020; 11: e00215.
• Dalan R, Bornstein SR, El-Armouche A, et al. The ACE-2 in COVID-19: Foe or Friend?Horm Metab Re 2020; 52: 257-63.
• Chen Z-GZ, You D. Influencing factors of pancreatic microcirculatory impairment in acute panceatitis. World J Gastroenterol 2002; 8: 406-12.
• Cheung S, Fuentes AD, Fetterman AD. Recurrent acute pancreatitis in a patient with COVID-19 Infection. Am J Case Rep 2020; 21: e927076.
• Patnaik RNK, Gogia A, Kakar A. Acute pancreatic injury induced by COVID-19. IDCases 2020; 10: e00959.
• Szatmary P, Arora A, Raraty MGT, Dunne DFJ, Baron RD, Halloran CM. Emerging phenotype of severe acute respiratory syndrome-Coronavirus 2-associated pancreatitis. Gastroenterology 2020; 159: 1551-4.
• Suchman K, Raphael KL, Liu Y, Wee D, Trindade AJ. Northwell COVID-19 Research Consortium. Acute pancreatitis in children hospitalized with COVID-19. Pancreatology 2021; 21: 31-3.
• Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in covid-19 with fatal outcome : results from a prospective, single-center, clinicopathologic case series. Ann Intern Med 2020; 173: 350e61.